Swedish Licence Allows Xbrane to Import Medicines and Release Batches in the EU
Key Facts
Xbrane Biopharma said the Swedish Medical Products Agency had granted it a licence to import medicines manufactured outside the European Union and European Economic Area, and to certify and release their batches for supply within the EU. The authorisation adds the import stage and associated batch release to the company’s operational capabilities, according to its statement. The company said products manufactured in third countries can enter the EU and then undergo Qualified Person certification and release. These steps must comply with the EU’s applicable good manufacturing practice requirements. The announcement relates to the company’s product supply chain but does not announce new sales or an additional commercial launch.
Xbrane said the licence gives it an opportunity to simplify the existing commercial supply chain for Ximluci and increase its control over import and batch-release activities. It said the simplification is expected to cover the Ximluci/Lucamzi supply chain, including the supply of finished products to the United States. The potential operational effect of the authorisation would therefore extend to product flows to the U.S. market, although the authorisation itself covers imports and batch release for supply within the EU. The company did not specify the amount of savings or when the supply-chain change would take place. It also did not cite a specific financial impact from the licence.
The authorisation comes as Ximluci, the company’s biosimilar to ranibizumab, is already on the European market; Xbrane said it received marketing authorisation there and was launched during 2023. In its third-quarter 2026 report, the company recorded revenue of 54.8 million Swedish kronor in the period from July to September, compared with 10.1 million in the corresponding period of 2025. Ximluci product sales were 54.6 million kronor for the quarter, compared with 9.9 million a year earlier. Revenue for the period from January to September 2026 was 118.9 million kronor, down from 143.3 million in the same period of 2025. Ximluci sales rose to 118.4 million kronor in the nine months from 58.6 million, while licensing revenue fell to 0.5 million from 84.7 million.
The company said the operational infrastructure provided by the licence could support Xdarzane, its biosimilar candidate to daratumumab, as well as future biosimilars. The authorisation, according to Xbrane, allows it to expand the services it offers partners to include importing products into the EU, Qualified Person certification and batch release. The company lists these services alongside biosimilar development and work to establish commercial manufacturing operations for them. This suggests the potential benefits of the licence include operations that can be offered to partners, as well as support for the company’s existing and candidate products. The statement did not announce a new partnership agreement or a launch date for Xdarzane.
The company reported cash and cash equivalents of 37.4 million Swedish kronor at the end of September 2026, compared with 93.6 million at the end of the corresponding period of 2025, according to its nine-month interim report. After the third quarter, Xbrane announced on 27 October that the U.S. Food and Drug Administration had approved the biologics licence application for its ranibizumab biosimilar candidate, and said it would work with its partners towards a U.S. launch. The company also reported that enrolment had been completed in the pivotal clinical study of Xdivane, which included about 340 patients. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. These developments place the Swedish licence within the company’s efforts to expand supply operations and work with its products and partners.